Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?

26 Jul 2019

Abstract excerpt

Controlled Human Infection Models (CHIMs) now exist for several infectious diseases. CHIMs offer significant insight into disease pathogenesis, as well the potential to rapidly test clinical proof-of-concept of vaccine candidates. The application of CHIMs to identify a correlate of protection that may reduce the sample size of, or obviate the need for clinical efficacy studies to achieve licensure is of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clostridium difficile and Clostridium perfringens research
Share to Escherichia coli research studies
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31358238
DOI: 10.1016/j.vaccine.2019.03.036

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?PMID 31358238Read ↗

Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity scoreSemantic proximity Read ↗

Animal models of shigellosis: a historical overviewSemantic proximity Read ↗

Status of vaccine research and development for ShigellaSemantic proximity Read ↗

Recent advances in modelling Shigella infectionSemantic proximity Read ↗

Frontiers in Shigella Vaccine DevelopmentSemantic proximity Read ↗

Considerations in planning a controlled human infection model in at-risk groups in sub-Saharan Africa: the case for pneumococcal challenge in people living with HIV in Malawi and a report of stakeholder consultationSemantic proximity Read ↗

Considerations in planning a controlled human infection model in at-risk groups in sub-Saharan Africa: the case for pneumococcal challenge in people living with HIV in Malawi and a report of stakeholder consultationSemantic proximity Read ↗

Planning robust clinical trials for Shigella vaccines: A simulation-based evaluation of the impact of naturally-acquired immunity on vaccine performanceSemantic proximity Read ↗

Vaccine-enhanced disease: case studies and ethical implications for research and public healthSemantic proximity Read ↗

Evaluating Shigella flexneri Pathogenesis in the Human Enteroid ModelSemantic proximity Read ↗

Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protectionSemantic proximity Read ↗

Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE ConferenceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.